Press Releases July 13, 2026 09:00 AM

Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call

Fortrea Sets Date for Q2 2026 Earnings Release and Conference Call

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
FTRE

Fortrea, a global contract research organization (CRO), announced it will release its Q2 2026 financial results on July 29, 2026, with a conference call scheduled for 8:00 a.m. ET to discuss the results. The company provides clinical development solutions to the life sciences sector, serving biopharmaceutical, biotechnology, and medical device companies worldwide.

Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
FTRE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Fortrea will release Q2 2026 financial results on July 29, 2026, before market open.
  • A conference call will be held at 8:00 a.m. ET to discuss financial results.
  • The company specializes in clinical trial management and consulting for the life sciences industry, operating in about 100 countries.

DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call.

The live webcast can be accessed at investors.fortrea.com. A replay will be available in the Events and Presentations section of the site following the conclusion of the call.

About Fortrea

Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea’s solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn, X and Bluesky.

Fortrea Contacts

Tracy Krumme (Investors) – 984-385-6707, [email protected]

Sue Zaranek (Media) – 919-943-5422, [email protected]

Kate Dillon (Media) – 646-818-9115, [email protected]


Risks

  • Uncertain financial performance in Q2 2026 which may impact investor sentiment.
  • Potential market volatility linked to earnings announcements in the CRO and biotechnology sectors.
  • Dependency on continued demand for clinical development services from biopharmaceutical and medical device companies.

More from Press Releases

General Fusion Becomes First Publicly Listed Fusion Company Jul 13, 2026 Old National Bank Foundation celebrates 20 years, $40+ million in Community Impact Jul 13, 2026 Genco Shipping & Trading Limited Comments on Extension of $24.80 Per Share Tender Offer by Diana Shipping Jul 13, 2026 Exyn COO Ben Williams to Discuss the Future of Autonomous Robotics in Live Industry Interview: The Future of 3D Scanning is Autonomous Jul 13, 2026 Scott Gill Appointed Vice President of Technology and Operations at TEGNA Jul 13, 2026